Pseudo-Hurler polydystrophy
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Overview
Pseudo-Hurler polydystrophy, also referred to as mucolipidosis III (ML III), is lysosomal storage disease closely related to I-cell disease (ML II). Symptoms of ML III are often not noticed until the child is 3-5 years of age.
Pathophysiology
Pathophysiology
As in ML II, ML III results from genetic defects in GlcNAc phosphotransferase (N-acetylglucosamine-1-phosphotransferase). However, ML III produces less severe symptoms and progresses more slowly, probably because the defect in GlcNAc phosphotranspherase lies in its protein recognition domain.[1] Therefore, the catalytic domain retains some of its activity, resulting in a smaller accumulation of carbohydrates, lipids, and proteins in the inclusion bodies.
Presentation
Presentation
Patients with ML III are generally of normal intelligence (trait) or have only mild mental retardation. These patients usually have skeletal abnormalities, coarse facial features, short height, and corneal clouding. Some individuals with ML III survive until their fourth or fifth decade of life.
References
References
- ↑ Murray, R, Granner, D, and Rodwell, V. (2006). Harper’s Illustrated Biochemistry. 27th ed. New York: Lange Medical Books/McGraw-Hill.
- Template:NINDS – original text of article derived from detail sheet available here
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH